The Effect of Persistent Foramen Ovale Closure on Migraine Remains an Enigma⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Wilmshurst, Peter
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he Effect of Persistent
oramen Ovale Closure on
igraine Remains an Enigma*
eter Wilmshurst, MB CHB, FRCP
hrewsbury, United Kingdom
he report in this issue of JACC: Cardiovascular Interven-
ions from Vigna et al. (1) raises more questions about a
onfusing area of medicine—the role of persistent foramen
vale (PFO) closure in migraine.
Persistent foramen ovale is associated with a number of
iseases including migraine with aura, cryptogenic stroke,
nd decompression illness (2–4). Other right-to-left shunts
re also associated with these conditions, which suggests
hat a right-to-left shunt per se has an etiological role (5). It
s postulated that in some people with migraine with aura a
rigger substance passes across a shunt, but if this is so the
rigger has not been identified. If this postulated mechanism
s responsible for some cases, it cannot account for all
ecause not all migraine sufferers have a shunt and many
eople with a shunt do not have migraine.
See page 107
Support for this hypothesis came from reports that, when
atients who suffered presumed paradoxical embolism had
heir PFO closed to prevent recurrence, there was dramatic
mprovement in migraine in the majority of cases and often
essation of migraine (6–8). An improvement was also
ound in patients who had migraine without aura (6). These
eports of improvement in migraine were from nonrandom-
zed observational series. A placebo effect could not be
xcluded, although in the early series the patients had no
rior expectation that PFO closure would have an effect on
igraine and the magnitude of the effect was greater than
reviously reported for any placebo response. However, in
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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s defending the libel action.ome patients migraine was not improved by PFO closure.
n a few migraine became more frequent or severe, and
ccasionally PFO closure triggered migraine in people who
ad not had it before, particularly soon after the closure
rocedure. This could be modified by clopidogrel (9).
Publication of the results of the MIST (Migraine Inter-
ention with STARFlex Technology) trial in March 2008
ade unraveling the association between PFO and migraine
ore difficult (10). The MIST trial was a prospective
ulticenter randomized double-blind controlled trial to
ompare the effect of closure of moderate or large PFOs
ith the STARFlex implant and sham intervention in
atients with severe and frequent migraine. The patients in
he MIST trial differed from those in earlier observational
tudies, because patients with a history of stroke were
xcluded. They usually had more severe migraine. In the
IST trial, follow-up was for 6 months, with the patients
eceiving aspirin and clopidogrel for the first 3 months, and
he headache analysis phase was during the second 3-month
eriod.
The initial findings of MIST were encouraging, with
0.2% of patients found to have a right-to-left shunt, the
ajority of which were classified as a moderate or large
FO. One hundred forty-seven patients were randomized
o either implantation of a STARFlex device or sham
ntervention. The final comparisons of the implant and
ham groups showed no effect on the primary end point of
essation of migraine or secondary end points of improve-
ent in migraine in either the intention-to-treat analysis or
er-protocol population. The latter excluded the patients
ho were withdrawn because of adverse events or failure to
ross or close a PFO. The implant arm had a high rate of
rocedural complications.
Vigna et al. have investigated the effects of PFO closure
n a case control study of patients who seem to be clinically
ntermediate between the patients in the MIST trial and the
bservational studies of PFO closure in stroke patients.
heir migraine was less severe than in the MIST trial but
ore severe than in observational studies. They had not had
troke but had subclinical magnetic resonance imaging brain
esions that might represent silent cerebral ischemic events.
agnetic resonance imaging brains scans were not per-
ormed in the MIST trial, but magnetic resonance imaging
rain lesions are common in migraineurs, so it is certain that
ome of the patients in the MIST trial had brain lesions.
nlike MIST, patients with migraine without aura were
ncluded in the study by Vigna et al., and they had 6
onths’ assessment of migraine headaches before they were
ffered a closure procedure. Critically, there was no blinding
f subjects to treatment. Eighty-two patients were offered a
losure procedure “for prevention of white matter lesions
rogression or thromboembolism.” The 29 who declined
losure became the control group, and self-selection might
ave influenced outcomes in the 2 groups. The control
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115roup had their preventive medical therapy adjusted by a
eurologist, who was in some way blind to the protocol, but
hose who had a closure procedure were not allowed
reventive medication. Fifty-three patients had a closure
rocedure with a variety of devices. Antiplatelet medication
as given for 6 months (rather than 3 months in MIST),
nd migraine symptoms were assessed for 6 months after
he end of antiplatelet treatment (3 months in MIST). In
he patients who had a closure procedure but not in control
ubjects, there were significant reductions in number of
igraine attacks and disabling attacks. Compared with the
edically treated control group, closure resulted in statisti-
ally significant and clinically important greater numbers of
atients who had cessation of migraine attacks, cessation of
isabling attacks, and over 50% reduction in migraine
ttacks.
Overall, the findings in the study by Vigna et al. (1)
ccord with results in open observational studies in patients
ith stroke and migraine. Therefore, we are left with a
ilemma. Why are there such different results between the
nly randomized double-blind sham-control trial, the
IST trial, and all other trials? It is possible that in patients
ith migraine the placebo effect from an operative inter-
ention might be much greater than the magnitude of
lacebo effects with drug treatments. There might be
undamental differences between migraineurs who have had
troke or cerebral ischemic injury and those without isch-
mic injury. Failure of migraine to respond to medical
reatment, as required for entry in the MIST trial, might be
n indication that there will be little response to PFO
losure. The methods of patient selection might have
esulted in unidentified differences between patients in the
IST trial and other studies. It is possible that in the
IST trial the analysis phase of the trial was too soon after
mplantation when there was inadequate device endotheli-
lization, a residual effect from antiplatelet treatment or an
arly post-closure migraine-exacerbation effect. Does resid-
al shunting, either atrial or pulmonary, play any part in
ailure of migraine to respond to PFO closure? If so, should
tudies of PFO closure require independent echocardiogra-
hy core laboratory assessment of residual shunting, com- oarable to coronary stenosis assessment in coronary inter-
ention studies, and full reporting of the findings?
The report by Vigna et al. (1) does not explain the
elationship between PFO and migraine, but it does raise
ore questions, particularly with regard to the need for
urther double-blind sham-controlled trials of PFO closure
or migraine.
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